Clinical and Quality-of-Life Outcomes of Omalizumab Treatment in Chronic Spontaneous Urticaria
Related Experiment Video
Updated: Jun 26, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Aims:
To evaluate response to omalizumab in chronic spontaneous urticaria (CSU), assess concordance between symptom and quality-of-life scores, and identify predictors of response.
Methods:
Single-centre retrospective review of adults with CSU treated with omalizumab in a dermatology department in the Midwest of Ireland. Data included demographics, disease duration, and baseline and latest Urticaria Severity Score (USS), Dermatology Life Quality Index (DLQI), and itch and rash scores. Responders were defined as ≥50% USS improvement. Associations were analysed using Spearman's correlation and Cohen's κ.
Results:
Thirty-six patients were included; 22 (61%) responded, including 11 complete responders. Complete responders had lower baseline USS and DLQI. Correlations between USS and other measures were moderate, with slight-moderate agreement.
Discussion:
Omalizumab improved CSU outcomes. Lower baseline severity predicted complete response, while symptom and quality-of-life improvements showed limited individual concordance.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma III: Clinical Manifestations
Asthma-III: Symptoms and Complications
Classification of Asthma
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: